Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
221
resultados
Última actualización
01/05/2026 [07:09:00]
Resultados 100 a 125 de 221
Resumen de: US20260108474A1
A PAMAM-based protein degradation system and a method of preparation and use thereof are provided. The protein degradation system comprises: a silica nanoparticle core; and a poly(amidoamine) dendrimer (PAMAM) layer coated on a surface of the silica nanoparticle, wherein the PAMAM layer is linked via amide bonds to three small-molecule ligands: MDM2 protein ligand Idasanutlin, GLUT1 protein ligand Lavendustin B and E3 ubiquitin ligase ligand Thalidomide-NH—CH2—COOH. The nanoparticle protein degradation system cooperatively degrades MDM2 protein and GLUT1 protein. This cooperative degradation strategy not only effectively suppresses proliferation and energy metabolism of tumor cells, but also significantly enhances the stability of p53 protein. By restoring the normal function of p53 protein, tumor cell growth is further inhibited, providing a new strategy for cancer therapy.
Resumen de: US20260108536A1
Aspects of the disclosure relate to a composition and methods for treating breast cancer using a cannabinoid-based nanoplatform. The composition comprises phytocannabinoids, including THC, CBD, CBG, and CBC, incorporated into nanoparticles for enhanced bioavailability and controlled release. The method involves administering the composition to patients with breast cancer, particularly stages I and II, to inhibit VEGF pathways and induce apoptosis. The treatment targets estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), HER2-positive, and triple-negative breast cancers. Aspects of the disclosure further provide the production of the composition using nano emulsification techniques to create nanoparticles smaller than 200 nm. This composition offers a novel, targeted approach to reducing tumor growth and metastasis in breast cancer patients.
Resumen de: US20260108539A1
This document presents a novel composition and method for treating osteoarthritis using a cannabinoid-based nanoplatform administered via intra-articular injection. The composition includes phytocannabinoids such as CBG and CBC, along with hyaluronic acid, type II collagen, and calcium gluconate, embedded within a nanoplatform designed to enhance bioavailability and ensure controlled release in the synovial space. Tailored for osteoarthritis patients, the treatment alleviates joint pain, stiffness, reduced mobility, inflammation, sensations of friction, muscle weakness, and joint deformity. Cannabinoids act through multiple mechanisms, including interaction with CB1 and CB2 receptors, cytokine modulation, inhibition of NF-κB, and activation of the TRPV1 receptor, providing a potent anti-inflammatory effect. The formulation aims to halt cartilage degeneration, reduce pain, and slow osteoarthritis progression. The production process uses nanoemulsification techniques to create particles smaller than 200 nm, with pre-sterilization through membrane filtration, ensuring both efficacy and safety.
Resumen de: WO2026084761A2
Disclosed are lipid nanoparticle formulations comprising a lipidoid as defined in the application. Also disclosed are nanoparticle compositions comprising a lipidoid of the invention that are capable of delivering a therapeutic agent. The application also discloses a pharmaceutical composition comprising a lipidoid composition of the invention.
Resumen de: WO2026085256A1
The present disclosure relates to lipids and compositions thereof. In various aspects of the disclosure, the compositions are lipid nanoparticle compositions that are used as adjuvants used with vaccines, such as RNA vaccines, and/or to prevent or treat diseases or disorders in a subject in need thereof.
Resumen de: US20260108475A1
Methods for inserting a targeting moiety (such as an antigen-binding protein moiety, a fragment antigen-binding moiety, or the like) into a lipid nanoparticle and compositions resulting from such methods are provided. The methods generally utilize a reaction that forms targeted nanoparticles by combining a targeting moiety and a lipid nanoparticle. A quenching operation is then provided by cooling the reaction to a temperature that stops the insertion of the targeting moiety. The reaction substantially preserves the integrity of a nucleic acid cargo (such as an mRNA encoding a VHH binding molecule).
Resumen de: US20260108473A1
0000 The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., hematopoietic stem cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.
Resumen de: US20260108622A1
Provided herein are non-PEGylated lipid nanoparticles comprising an outer polyanionic layer, compositions thereof, and methods of using said particles or compositions for therapeutic applications.
Resumen de: WO2025042791A1
The disclosure provides for compositions that comprise nanocomplexes formed by complexing one or more therapeutic agents with nucleic acid fragments of varying lengths and sizes that are coated or complexed with protamine sulfate, and uses thereof, including for the treatment of cancer in a subject in need thereof.
Resumen de: US2024417680A1
0000 The application pertains to compositions and methods useful for growing living cells such as stem cells. The compositions employ a mixture of an extracellular matrix and discrete carbon nanotubes. The extracellular matrix may also comprise components selected from the class of proteins, proteoglycans, polysaccharides, lipids, peptides, messenger molecules, signaling molecules, or any mixture thereof. The discrete carbon nanotubes are usually less than about 1% by weight of the dry weight of the total composition.
Resumen de: WO2024259356A1
Compounds are provided having the following Formula (I): or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein G1, G2, R1, R2, R3, L1a, L1b, and L2 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Resumen de: EP4729075A1
0001 The present application relates to the field of biomedicine, and provides an epigenetic editing tool for targeting a hepatitis B virus gene and a use thereof.
Resumen de: WO2024259175A2
Provided herein is a system for inhibiting a miRNA-17 family miRNA from binding to the 3'UTR of PKD1, where the system includes: a gRNA; and a polynucleotide-programmable nucleotide-binding domain, where the system modifies a binding site of a miRNA-17 family miRNA in the 3'UTR of PKD1, thereby preventing binding of the miRNA-17 family miRNA and de-repressing PKD1 mRNA.
Resumen de: WO2024256962A1
The invention relates to RNA molecules encoding an E. coli fimbrial H antigen (FimH). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA 5 molecules, RNA-LNPs and compositions for the prevention of E. coli infection, including urinary tract infection.
Resumen de: EP4729051A2
0001 The present invention relates to a method to prepare golf ball like microparticles by spray drying of nanosuspensions of nanoparticles or solutions for dry powder inhalers for use in the treatment and prevention of pulmonary diseases.
Resumen de: WO2024259315A1
Compounds are provided having the following Formula (I): (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein G1, R1, R2, R3, L1, and L2 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Resumen de: EP4729507A1
Provided is a rapidly-metabolized lipid compound. The present invention relates in particular to a compound represented by formula (I), or a pharmaceutically acceptable salt, an isotopic variant, a tautomer or a stereoisomer thereof. Also provided are a nanoparticle pharmaceutical composition comprising the compound, and a use of the compound and a composition thereof in delivering nucleic acids.
Resumen de: WO2024259322A1
Compounds are provided having the following Formula (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, G1, G2, L1, and L2 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Resumen de: KR102631907B1
The present invention relates to a device useful for manufacturing nanoparticles containing hydrophobic substances and hydrophilic substances. Specifically, the device of the present invention comprises: a plurality of inlet channels through which hydrophobic substances and hydrophilic substances are respectively introduced; a mixing channel through which the substances are mixed to manufacture nanoparticles; and an outflow channel through which the manufactured nanoparticles are discharged, wherein the mixing channel includes micro-pillars capable of increasing the mixing efficiency of the substances. Therefore, the nanoparticles manufactured by the device of the present invention have excellent particle uniformity and may be usefully used as drugs or drug delivery vehicles.
Resumen de: WO2024258949A2
Disclosed herein are immunosorbent nanoparticles, devices, and methods for selective removal of a target protein such as beta-2 microglobulin (B2M) from a liquid such as blood.
Resumen de: WO2024259421A2
A nanoparticle generally comprising a targeting peptide-lipid conjugate, wherein a targeting peptide moiety of the targeting peptide-lipid conjugate comprises a GRP78 targeting peptide, a polyethylene glycol (PEG)-lipid conjugate, a drug-lipid conjugate comprising a prodrug moiety, wherein the drug-lipid conjugate comprises one or more of a mertansine (DM1) prodrug, a doxorubicin prodrug, and a bortezomib (BTZ) prodrug; and wherein the prodrug is linked to a lipid moiety of the drug-lipid conjugate via a phosphodiester bond or a boron ester bond; cholesterol comprising about 1 mol% to about 10 mol% of the nanoparticle; and distearoylphosphatidylcholine (DSPC).
Resumen de: WO2024254709A1
The present disclosure provides a therapeutic nanodisk, the therapeutic nanodisk comprising: a lipid-binding polypeptide; a lipid bilayer and a therapeutic agent, wherein the therapeutic agent may be of use for treating, preventing a central nervous system disease, disorder, trauma or injury; or as a diagnostic agent for diagnosing a central nervous system disease, disorder, trauma or injury. The lipid bilayer may be 1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and the therapeutic agent may be a nucleic acid polymer. Further provided are methods for administration of the therapeutic nanodisk to treat, prevent or diagnose the central nervous system disease, disorder, trauma or injury and uses of such therapeutic nanodisks.
Resumen de: WO2024254703A1
The blood-brain barrier (BBB) and the blood-cerebrospinal fluid (CSF) barrier (BCSFB) create an obstacle for effective systemic drug delivery to the CNS. This application provides compounds and nanoparticles for increasing the penetration of drugs through the BBB. Specifically, this application provides nanoparticles for the diagnosis and treatment of central nervous system (CNS) diseases and preparation methods therefor. These nanoparticles are polymer-lipid based nanoparticles (PLNPs) functionalized to facilitate blood brain barrier (BBB) penetration and accumulation in a disease area of the CNS. Notably, said nanoparticles target an LDL receptor and/or glucose transporter. In various embodiments, the nanoparticles comprise terpolymers which comprise polysorbates (such as polysorbate 80), poly acrylic acids (such as poly methacrylic acid (PMAA)) and various polysaccharides (including maltodextrin) and the nanoparticles also comprise cholesterol and lipids. The nanoparticles encapsulate a pay load which is a therapeutic drug molecule, biomolecule, contrast agent or nucleotide.
Resumen de: WO2024259281A2
Poly(oxazoline) conjugates with pendant cationic groups (cationic POZ) and lipid nanoparticles (LNPs) including cationic POZ used to facilitate delivery of an encapsulated payload. LNPs and polyplexes including cationic POZ and a nucleic acid payload such as, but not limited to, mRNA or modified mRNA are disclosed. Such LNPs have no immunogenicity or reduced immunogenicity as compared to a corresponding LNP containing an ionizable lipid.
Nº publicación: EP4727969A2 22/04/2026
Solicitante:
RETHINK64 BIONETWORKS PBC [US]
Resumen de: WO2024259374A2
To introduce material to cells, contemporary medicinal constructs rely on the uptake mechanisms of the cell membrane. This puts major restrictions on the types of utilizable materials (e.g., charge compatible), specifications (e.g., 100 nanometer scale or less) and organizations (mostly simplistic spheroids); this is the regime of nanoparticles, protein/peptide conjugates etc. However, the focus and novelty of the innovation presented are constructs which can still achieve this membrane interaction to connect to cells yet the constructs themselves remain outside of the cell, thus establishing a network by which to transfer materials. These can surpass the aforementioned limitations as well as create entirely new application spaces as these new constructs enable different desired distribution patterns and exchanged material.
BOPI
Sede Electrónica
